SUNPHARMA.NSSUNPHARMA.NSNSE
Loading
EBITDA Margin Over TimeStable
Percentile Rank50
3Y CAGR+2.7%
5Y CAGR+6.4%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+2.7%/yr
vs +5.7%/yr prior
5Y CAGR
+6.4%/yr
Recent deceleration
Acceleration
-2.9pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
5 yr
Consecutive growthStable
PeriodValueYoY Change
202528.47%+7.2%
202426.55%+0.0%
202326.55%+1.1%
202226.27%+5.4%
202124.91%+19.3%
202020.88%-6.1%
201922.23%+5.4%
201821.08%-32.8%
201731.34%+3.1%
201630.41%-